期刊
JOURNAL OF HEPATOLOGY
卷 76, 期 3, 页码 681-693出版社
ELSEVIER
DOI: 10.1016/j.jhep.2021.11.018
关键词
HCC; survival; BCLC; ablation; surgery; liver transplantation TACE; TARE; systemic treatment; ALBI score; AFP
资金
- Instituto de Salud Carlos III [PI15/00145, PI18/ 0358, PI13/01229, PI18/00542, PI19/00742, PI18/00768]
- Spanish Health Ministry (National Strategic Plan against Hepatitis C)
- European Association for the Study of the Liver (EASL)
- ISCIII/EU TRANSCAN-2 [AC16/00065]
- National Institute of Health [R01 R01 MD012565]
- AECC [PI044031]
- European Union [952103]
There have been significant advances in the treatment strategies for hepatocellular carcinoma since the last update in 2018. However, some interventions still lack sufficient data for clinical incorporation, and personalized clinical management requires consideration of multiple parameters.
There have been major advances in the armamentarium for hepatocellular carcinoma (HCC) since the last official update of the Barcelona Clinic Liver Cancer prognosis and treatment strategy published in 2018. Whilst there have been advances in all areas, we will focus on those that have led to a change in strategy and we will discuss why, despite being encouraging, data for select interventions are still too immature for them to be incorporated into an evidence-based model for clinicians and researchers. Finally, we describe the critical insight and expert knowledge that are required to make clinical decisions for individual patients, considering all of the parameters that must be considered to deliver personalised clinical management. (C) 2021 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据